Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient‐Reported Disability Measure and Self‐Administered Neuroperformance Outcomes
Annals of Neurology · 2026-09 · 100 (3) · 525-546
DOI: 10.1002/ana.78275 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Neurology, online erschienen am 06.07.2026. Verfasst von Evy M Reinders und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology - Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma…. Hauptthemen laut MEDLINE: Disease Progression, Disability Evaluation, Patient Reported Outcome Measures, Multiple Sclerosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The objective of this study was to investigate the ability of patient‐reported/administered outcomes to capture disability worsening and progression independent of relapse activity (PIRA) in multiple sclerosis (MS).
Methods
We included patients from the longitudinal multicenter MS PATHS cohort with ≥3 assessments and >6 months follow‐up. PIRA was defined on the patient‐determined disease steps (PDDS) and self‐administered tests assessing walking speed, manual dexterity, and processing speed, in the absence of self‐reported relapses. We assessed (i) prevalence of PDDS/self‐administered test‐based disability worsening and PIRA definitions; (ii) their concurrent validity, through the association with worsening and PIRA definitions based on the expanded disability status scale (EDSS; Barcelona subcohort); and (iii) their clinical meaningfulness, through the correlation with brain magnetic resonance imaging (MRI) and quality‐of‐life (QoL) data trajectories.
Results
We included 9,088 patients (73% female patients; age = 46.8 years; disease duration = 14.2 years). Over a 3‐year follow‐up, 4,066 (45%) patients worsened on ≥1 patient‐reported/administered outcome, of which 2,357 (58%) developed PIRA. In the Barcelona subcohort (N = 279), 68 (24%) patients developed EDSS‐based worsening, of which 30 (44%) developed EDSS‐based PIRA; 99 of 279 (35%) worsened on ≥1 patient‐reported/administered test, of which 78 of 99 (79%) had PIRA. Worsening (but not PIRA) on PDDS was associated with EDSS‐based worsening (odds ratio = 3.03 [1.42; 6.43], p = 0.004). PDDS/self‐administered‐test‐based worsening or PIRA strongly correlated with accelerated brain atrophy and T2 lesion volume increase compared to non‐worseners ( p < 0.05), and showed worse QoL ( p < 0.05).
Interpretation
Despite only partial agreement with EDSS‐based definitions, PDDS/self‐administered test‐based worsening and PIRA definitions were clinically meaningful, by identifying patients with greater brain damage and poorer QoL, supporting their use in clinical practice. ANN NEUROL 2026;100:525–546
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurology - Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Section of Neuroradiology, Department of Radiology (IDI), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), ISCIII, Madrid, Spain.
- Neuroimmunology Unit, and Director of the Multiple Sclerosis Center at the University of Rochester, Rochester, NY, USA.
- Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
ORCID-Profile: René Carvajal, Álvaro Cobo-Calvo, Luca Bollo, Manuel Comabella, Neus Mongay-Ochoa, Andreu Vilaseca, Ana Zabalza, Deborah Pareto, Menno Schoonheim, Jaume Sastre-Garriga, Tjalf Ziemssen, Àlex Rovira
Zitieren
APA
Reinders, E. M., Masot-Llima, A., Otero-Romero, S., Carvajal, R., Cobo-Calvo, Á., Carbonell-Mirabent, P., Beltran, J., Arévalo, M. J., Ariño, H., Arrambide, G., Auger, C., Bollo, L., Castilló, J., Comabella, M., Galán, I., García-Sarreón, A., Goodman, A., Hersh, C. M., La Puma, D., …, & Tur, C. (2026). Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient‐Reported Disability Measure and Self‐Administered Neuroperformance Outcomes. Annals of Neurology, 100(3), 525-546. https://doi.org/10.1002/ana.78275
Vancouver
Reinders EM, Masot-Llima A, Otero-Romero S, Carvajal R, Cobo-Calvo Á, Carbonell-Mirabent P, et al. Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient‐Reported Disability Measure and Self‐Administered Neuroperformance Outcomes. Annals of Neurology. 2026;100(3):525-546. doi:10.1002/ana.78275
BibTeX
@article{Reinders2026,
author = {Reinders, Evy M and Masot-Llima, Ariadna and Otero-Romero, Susana and Carvajal, René and Cobo-Calvo, Álvaro and Carbonell-Mirabent, Pere and Beltran, Jordina and Arévalo, Maria Jesús and Ariño, Helena and Arrambide, Georgina and Auger, Cristina and Bollo, Luca and Castilló, Joaquín and Comabella, Manuel and Galán, Ingrid and García-Sarreón, Alexis and Goodman, Andrew and Hersh, Carrie M and La Puma, Delon and Hua, Le H and Midaglia, Luciana and Mongay-Ochoa, Neus and Mowry, Ellen M and Pappolla, Agustín and Rodríguez-Acevedo, Breogán and Río, Jordi and Tagliani, Paula and Vidal-Jordana, Ángela and Vilaseca, Andreu and Zabalza, Ana and Pareto, Deborah and Nos, Carlos and Schoonheim, Menno and Strijbis, Eva and Sastre-Garriga, Jaume and Tivarus, Madalina and Ziemssen, Tjalf and Rovira, Àlex and Montalban, Xavier and Tintoré, Mar and Tur, Carmen},
title = {Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient‐Reported Disability Measure and Self‐Administered Neuroperformance Outcomes},
journal = {Annals of Neurology},
year = {2026},
volume = {100},
number = {3},
pages = {525--546},
doi = {10.1002/ana.78275}
}
EUVIMED